Drug Information

General Information
Drug ID
DR00651
Drug Name
Fenofibric acid
Synonyms
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid; 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoic acid; AK117112; BGF9MN2HU1; BRN 2058973; C17H15ClO4; CCRIS 7302; CHEBI:83469; CHEMBL981; EINECS 255-626-9; FNF Acid; LF 153; LF 178 acid; NSC 281318; Procetofenic acid; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-; Trilipix; UNII-BGF9MN2HU1; W-106287; alpha 1081
Drug Type
Small molecular drug
Indication Hypercholesterolemia [ICD11: 5C80.0] Approved [1]
Structure
3D MOL 2D MOL
Formula
C17H15ClO4
Canonical SMILES
CC(C)(C(=O)O)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
InChI
InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)
InChIKey
MQOBSOSZFYZQOK-UHFFFAOYSA-N
CAS Number
CAS 49562-28-9
Pharmaceutical Properties Molecular Weight 318.7 Topological Polar Surface Area 63.6
Heavy Atom Count 22 Rotatable Bond Count 5
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 4
XLogP
3.9
PubChem CID
64929
PubChem SID
103256438 , 103853918 , 104332417 , 118048388 , 118212615 , 125350317 , 126616576 , 126650397 , 126665945 , 128633517 , 134351110 , 135023245 , 135650256 , 136990671 , 137008576 , 139809304 , 143270 , 143755763 , 152028908 , 15988368 , 162175168 , 162263030 , 163415486 , 164785582 , 172913777 , 174529345 , 175265316 , 175611044 , 184538157 , 187072366 , 198991585 , 210279847 , 210282170 , 223352414 , 223385806 , 223448217 , 223519115 , 223669964 , 29203742 , 43121787 , 50022223 , 50826157 , 56312055 , 56314036 , 58097888 , 7671261 , 81049613 , 8189389 , 85171876 , 87359585
ChEBI ID
CHEBI:83469
TTD Drug ID
D0NF1U
DT(s) Transporting This Drug ABCA1 Transporter Info ATP-binding cassette sub-family A member 1 Substrate [2]
References
1 Fenofibric acid was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1193-7.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.